{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:34:34Z","timestamp":1790321674716,"version":"4.1.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T00:00:00Z","timestamp":1471478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","award":["PhD Scholarship"],"award-info":[{"award-number":["PhD Scholarship"]}],"id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161470","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T17:37:07Z","timestamp":1471541827000},"page":"e0161470","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-7602","authenticated-orcid":true,"given":"Laura N.","family":"Eadie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"key":"ref1","first-page":"1497","article-title":"A Minute Chromosome in Human Chronic Granulocytic Leukemia","volume":"132","author":"PC Nowell","year":"1960","journal-title":"Science"},{"issue":"5405","key":"ref2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"BJ Druker","year":"1996","journal-title":"Nat Med"},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"PW Manley","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"issue":"27","key":"ref5","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"LJ Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"JM Goldman","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"TP Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"FJ Giles","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"JS Khorashad","year":"2013","journal-title":"Blood"},{"issue":"18","key":"ref10","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"A Hochhaus","year":"2013","journal-title":"Blood"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3109\/10428194.2012.737919","article-title":"Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance","volume":"54","author":"A Camgoz","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"P le Coutre","year":"2000","journal-title":"Blood"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.20131","article-title":"Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr\/Abl protein","volume":"100","author":"B Scappini","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"C Tang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"E Weisberg","year":"2000","journal-title":"Blood"},{"issue":"20","key":"ref17","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming","volume":"29","author":"F Zhao","year":"2010","journal-title":"Oncogene"},{"issue":"19","key":"ref18","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"DJ Barnes","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-4608(02)00615-5","article-title":"BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration","volume":"139","author":"LJ Campbell","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cancergencyto.2007.09.003","article-title":"Translocation 3;21, trisomy 8, and duplication of the Philadelphia chromosome: a rare but recurrent cytogenetic pathway in the blastic phase of chronic myeloid leukemia","volume":"179","author":"E De Braekeleer","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"5531","key":"ref21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"A Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"S Branford","year":"2003","journal-title":"Blood"},{"issue":"25","key":"ref24","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"T Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"ref25","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"MC Muller","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"O Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"33","key":"ref27","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Y Dai","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"NJ Donato","year":"2003","journal-title":"Blood"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"S Grosso","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"ref30","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"FX Mahon","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-4-32","article-title":"Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line","volume":"4","author":"S Okabe","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"J Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"J Wu","year":"2008","journal-title":"Blood"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"LN Eadie","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"H Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"C Hirayama","year":"2008","journal-title":"Pharm Res"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"T Illmer","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"FX Mahon","year":"2003","journal-title":"Blood"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"FX Mahon","year":"2000","journal-title":"Blood"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"M Gromicho","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbrc.2013.05.022","article-title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells","volume":"435","author":"S Okabe","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"H Yuan","year":"2010","journal-title":"J Biol Chem"},{"issue":"23","key":"ref43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood.V126.23.348.348","article-title":"The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study","volume":"126","author":"LN Eadie","year":"2015","journal-title":"Blood"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V108.11.2144.2144","article-title":"ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance","volume":"108","author":"D White","year":"2006","journal-title":"Blood"},{"key":"ref45","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","author":"LN Eadie","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/10428194.2012.715345","article-title":"Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2","volume":"54","author":"LN Eadie","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"ref47","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells","volume":"84","author":"GL Nichols","year":"1994","journal-title":"Blood"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"D White","year":"2005","journal-title":"Blood"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"P Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"C Tanaka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"41","key":"ref51","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"MA Meyn 3rd","year":"2006","journal-title":"J Biol Chem"},{"issue":"52","key":"ref52","doi-asserted-by":"crossref","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","article-title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr","volume":"272","author":"M Warmuth","year":"1997","journal-title":"J Biol Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:46:59Z","timestamp":1601020019000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161470"}},"subtitle":[],"editor":[{"given":"Connie J","family":"Eaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161470","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]}}}